(BNR) Burning Rock Biotech Limited Marketing Mix Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(BNR) Burning Rock Biotech Limited Complete Analysis Pack
Unlock Strategic Clarity
This Burning Rock Biotech Limited 4P's Marketing Mix Analysis explains the company’s products, pricing approach, distribution channels, and promotion tactics and shows how they drive positioning and sales. This page contains a real preview/sample of the report so you can review style and content; purchase the full version to get the complete ready-to-use analysis.
Product
NGS cancer diagnostics
Burning Rock Biotech Limited’s NGS cancer diagnostics support therapy selection and prognosis assessment across solid tumors and blood cancers. In 2025, the product line stayed centered on clinically used sequencing panels that help doctors match treatment to tumor biology and monitor disease risk. This broad testing reach matters because the company serves both tissue and blood-based workflows in oncology.
OncoCompass IO
OncoCompass IO is Burning Rock Biotech Limited's liquid biopsy test in its flagship portfolio, built on circulating tumor DNA-based analysis. It is positioned for oncology decision support, helping guide treatment choices with noninvasive molecular data. As a 4P product, it stands out for clinical use, broad applicability, and fit with precision oncology workflows.
OncoScreen IO
OncoScreen IO is Burning Rock Biotech Limited's comprehensive pan-cancer tissue test for broad tumor profiling across cancer types. It uses tissue samples to support clinical insight, which helps guide biomarker review and treatment planning. For labs and hospitals, one tissue-based panel can reduce the need for multiple single-cancer tests.
ColonCore and ParpMatch
ColonCore tests microsatellite instability and key GI-cancer mutations, while OncoScreen ParpMatch and OncoCompass ParpMatch focus on homologous recombination deficiency genes. Together, they support biomarker-driven oncology testing, helping match patients to targeted therapy choices.
These assays sit in a fast-growing precision-oncology segment, where MSI and HRD status can change treatment selection and trial eligibility.
- ColonCore: GI cancer biomarker panel
- ParpMatch: HRD-related gene testing
- Supports targeted treatment selection
Myriad myChoice and DetermaRx
Burning Rock Biotech Limited’s China agreements for Myriad myChoice and DetermaRx widen its tumor-testing menu and add lung cancer risk stratification for the local market. The pull is real: China’s cancer burden was about 4.8 million new cases and 2.6 million deaths in 2022, so demand for precise testing stays high.
myChoice supports tumor testing, while DetermaRx helps assess recurrence risk in non-small cell lung cancer, which is a major use case in China. In 4P terms, this product line strengthens Product and Place by localizing advanced diagnostics for Chinese patients and hospitals.
- Expands Burning Rock’s test menu
- Targets China’s large cancer market
- Supports lung cancer risk stratification
Burning Rock’s 2025 Product Mix Centers on Precision Oncology Testing
Burning Rock Biotech Limited's Product mix in 2025 stayed centered on oncology NGS tests for tissue and liquid biopsy workflows. OncoCompass IO, OncoScreen IO, and ColonCore anchor biomarker-driven treatment selection, while ParpMatch and licensed assays widen coverage in HRD, lung, and GI use cases. China's 4.8 million new cancer cases in 2022 keep demand for precise testing high.
| Test | Use |
|---|---|
| OncoCompass IO | Liquid biopsy |
| OncoScreen IO | Tissue profiling |
| ColonCore | GI biomarkers |
What is included in the product
Detailed Word Document
Delivers a concise, company-specific breakdown of Burning Rock Biotech Limited’s Product, Price, Place, and Promotion strategy.
Editable Excel File
Condenses Burning Rock Biotech Limited’s 4Ps into a quick, structured snapshot that simplifies strategy review and decision-making.
Reference Sources
Consolidates primary industry reports, government datasets, and peer-reviewed sources so investors can quickly verify Burning Rock Biotech assumptions and shorten due diligence.
Place
Guangzhou headquarters
Burning Rock Biotech Limited is headquartered in Guangzhou, China, anchoring the Company in mainland China and keeping it close to hospitals, labs, and regulators. This base supports domestic commercialization and clinical collaboration, which matters in a market where China’s mainland accounted for the bulk of the Company’s operating footprint in 2025.
People’s Republic of China
Burning Rock Biotech Limited keeps the People’s Republic of China as its main distribution base, with diagnostic solutions built for Chinese clinical needs and sold into that market. In 2025, China’s large oncology testing demand still made it the key geography for the Company’s core business, so market access, hospital ties, and local reimbursement drive sales more than overseas reach.
Central Laboratory Business
Central Laboratory Business is one of Burning Rock Biotech Limited’s operating segments, with tests run through centralized lab workflows. This lets Burning Rock serve patients nationwide without every site building full in-house sequencing capacity. In FY2025, this model still mattered most for scale, standardization, and faster access to molecular testing across China.
In-Hospital Business
Burning Rock Biotech Limited’s In-Hospital Business puts testing inside hospitals, so oncologists can order and review results faster at the point of care. That setup improves access for clinical oncology use and helps shorten the path from biopsy to treatment decision.
It also supports higher test adoption because physicians can use the service in routine hospital workflows, not through a separate outside channel.
- Closer to physicians and patients
- Faster clinical decision support
- Better hospital-based adoption
Pharma R&D services
Burning Rock Biotech Limited’s Pharma Research and Development Services link the CompanyName to pharma and biotech partners, so it earns beyond routine diagnostics. This channel supports biomarker work, trial support, and translational research, which deepens long-term client ties. It is the part of the mix that turns lab capability into partner revenue.
- Serves pharma and biotech clients
- Supports research and trials
- Expands revenue beyond diagnostics
Burning Rock’s 2025 China-First Place Strategy
Burning Rock Biotech Limited keeps its Place mix centered on mainland China, with Guangzhou as its base and China still the core market in 2025. Central laboratories widen reach nationwide, while in-hospital channels put testing closer to oncologists and patients. Pharma research services add another access point through partner labs and trial work.
| Place factor | 2025 signal |
|---|---|
| Headquarters | Guangzhou, China |
| Main market | Mainland China |
| Delivery model | Central lab + in-hospital |
Get Your Copy
Burning Rock Biotech Limited Reference Sources
The preview shown here is the actual Burning Rock Biotech Limited 4P’s Marketing Mix analysis you’ll receive instantly after purchase—fully complete and ready to use.
You’re viewing the exact same editable, high-quality document included in your order, not a sample or demo.
Buy with confidence: no surprises, immediate download, and practical insights on Product, Price, Place, and Promotion.
Promotion
Clinical trial collaborations
Burning Rock Biotech Limited uses clinical trial collaborations to raise scientific visibility for its assays and to support validation in real oncology settings. These partnerships help place its tests in investigator-led studies and multi-center trials, which can speed adoption by labs and cancer clinicians. In 2025/2026, that trial-led route is especially relevant as oncology diagnostics keep shifting toward evidence-backed, locally validated use.
AstraZeneca and Bayer
Burning Rock Biotech Limited’s collaborations with AstraZeneca and Bayer lift its profile with oncologists and researchers, because both names are widely trusted in cancer care. These ties add third-party credibility and help position Burning Rock as a partner in precision oncology, not just a test maker. That matters in a market where peer recognition can speed adoption and support clinical use.
Johnson & Johnson and Merck KGaA
Burning Rock Biotech Limited lists Johnson & Johnson and Merck KGaA as partners, and that works as indirect promotion through co-development and study work. Johnson & Johnson reported about $88.8 billion in 2024 sales, while Merck KGaA posted about €21.2 billion, so both names carry heavy oncology credibility. That kind of pharma-led link signals scientific relevance and can lift Burning Rock Biotech Limited's visibility with hospitals and researchers.
CStone and BeiGene
Burning Rock Biotech Limited’s ties with CStone and BeiGene widen its China oncology network and help speed patient recruitment for studies. They also strengthen local market access, which matters in a market where trial speed and physician reach can shape adoption. These links fit its focus on therapies with stronger clinical fit and commercial pull.
- Wider China oncology reach
- Faster study recruitment support
- Stronger local market presence
- Sharper therapy selection focus
License agreements
Burning Rock Biotech Limited uses license agreements with Myriad Genetics and Oncocyte to bring established tests into China under its own platform, so it can expand faster without building every assay from scratch. This approach supports broader brand recognition and lowers product-development risk.
It also helps Burning Rock sell tested, clinically known products in a market where China’s cancer burden is still rising, which keeps demand for advanced diagnostics high. Licensing is a practical route to add differentiated offerings while saving time versus full in-house development.
- Two key partners: Myriad Genetics and Oncocyte
- Imports proven tests into China
- Expands portfolio without full R&D build
Burning Rock Gains Credibility Through Big Pharma Partnerships
Burning Rock Biotech Limited promotes its oncology tests mainly through trial collaborations and licensing ties that build clinician trust and give it third-party validation. Partnerships with AstraZeneca, Bayer, Johnson & Johnson, Merck KGaA, Myriad Genetics, and Oncocyte widen reach, support study recruitment, and help position its assays as clinically proven.
| Partner | Promotion role | Value |
|---|---|---|
| Johnson & Johnson | Credibility | $88.8B sales |
| Merck KGaA | Credibility | €21.2B sales |
Price
No public list price
Burning Rock Biotech Limited does not publish a standard retail list price for its tests, so pricing appears to be contract-based rather than shelf-based. That fits how oncology diagnostics are usually sold to hospitals, labs, and partners, where rates depend on volume, assay type, and reimbursement terms. In its latest reported results, Burning Rock posted RMB 214.0 million in revenue for 2025, showing a B2B model where negotiated pricing matters more than public price tags.
Hospital contracting
Burning Rock Biotech Limited uses hospital contracting for in-hospital diagnostics, so price is set by procurement deals, not a fixed consumer list. Rates can change by site, test type, and order volume, which helps hospitals negotiate lower per-test costs on bigger runs. That model fits institutional buyers and supports reimbursement-linked sales, not walk-in retail pricing.
Central lab service fees
Burning Rock Biotech Limited usually charges central lab testing as a fee per assay or panel, with the final price tied to sample type, panel size, and test complexity. Liquid biopsy often costs more than tissue testing because it needs deeper sequencing and tighter quality control. In 2025, this fee model stayed the key revenue lever for central lab services.
Pharma research contracts
Pharma research contracts at Burning Rock Biotech Limited are usually priced as project deals, not fixed menus. Fees move with study scope, sample size, and how deep the analysis goes, so larger biomarker and sequencing projects cost more. In 2025, this kind of partner-led pricing stays the norm across biotech and pharma R&D outsourcing.
- Project-based pricing
- Scope drives fee levels
- Sample count raises cost
- Negotiated with pharma partners
Licensing and reimbursement dependent
Burning Rock Biotech Limited’s pricing for licensed tests is licensing and reimbursement dependent, so myChoice and DetermaRx can carry different price points by market, payer, and channel. Reimbursement rules, tender terms, and local access limits can move realized net price more than list price. Exact July 2026 prices are not publicly specified in the available information.
- Licensed tests may use separate pricing.
- Reimbursement can set net price.
- Tenders and access shape local pricing.
- July 2026 prices are not disclosed.
Burning Rock’s Pricing Stays Contract-Based in 2025
Burning Rock Biotech Limited’s price is mostly contract-based, not public list pricing, so hospitals, labs, and pharma partners negotiate by test type, volume, and reimbursement. In 2025, revenue was RMB 214.0 million, showing pricing still depends on institutional deals.
| Price driver | 2025 signal |
|---|---|
| Hospital contracts | Negotiated per site |
| Central lab fees | Per assay or panel |
| Pharma projects | Scope-based pricing |
| Licensed tests | Reimbursement-led |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.